Approval status

When Will Retatrutide Be FDA Approved? 2026 Regulatory Status Update

Published May 2, 2026Updated May 3, 2026Medical safety, official-source, and research-reference review

No FDA approval date is guaranteed. Retatrutide remains investigational as of May 2, 2026.

Direct answer

Retatrutide will only be FDA approved if Lilly submits the required application and FDA determines that the evidence supports approval for a specific use. Lilly has not announced a guaranteed approval date.

Research context

These references frame the evidence base behind this topic. They are not medical advice, approval, or instructions for using retatrutide outside a clinical trial.

Short source quoteagonist of the GIP, GLP-1, and glucagon receptors

Jastreboff et al., NEJM 2023 retatrutide phase 2 obesity trial

This peer-reviewed phase 2 paper is the anchor for retatrutide mechanism language. It does not make retatrutide approved or publicly available.

Short source quoterandomised, double-blind, placebo and active-controlled

Rosenstock et al., Lancet 2023 retatrutide phase 2 type 2 diabetes trial

The type 2 diabetes phase 2 paper helps separate controlled clinical research from online self-use claims.

Short source quoterandomized, double-blind, placebo-controlled trial

Sanyal et al., Nature Medicine 2024 retatrutide MASLD phase 2a trial

The MASLD substudy adds peer-reviewed evidence for metabolic research context, but it is still not public-use approval.

Short source quotecombining the activity of GLP-1, GIP, and glucagon

Bossart et al., Cell Metabolism 2022 GLP-1/GIP/glucagon triagonist study

This triagonist paper supports the broader triple-agonist mechanism discussion, not claims about any unapproved product sold online.

Short source quotebiological actions, and therapeutic relevance

Baggio and Drucker, Gastroenterology 2007 biology of incretins review

This review supports mechanism explanations around GLP-1 and GIP biology without turning mechanism into treatment advice.

What to know before acting on this search

Lilly says public launch depends on trial completion and the regulatory approval process.
Positive clinical trial results can support a submission, but they do not equal approval.
FDA review can result in approval, delay, request for more data, narrower labeling, or non-approval.

Safety and compliance notes

Do not treat predicted dates from blogs, forums, or seller pages as official timelines.
Pre-approval products claiming to be retatrutide are not FDA-approved medicine.
Approved alternatives may be available now with prescription and clinician supervision.

Safer next step

Use the FDA status page as the canonical update page for approval timing.

Medical disclaimer

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. I am not a medical professional. Always consult a qualified healthcare provider before starting, stopping, or changing any weight loss treatment. Individual results vary. Retatrutide is investigational and is not FDA approved. FDA-approved options such as semaglutide and tirzepatide require prescriptions and should only be used under medical supervision.

References

Public record review

Have a public record we should add?

Submit a public page, correction, or observation for documentation review. Submissions are evaluated for public-record value only, not to help people obtain products.

Submit a public record